Bruker bulks up preclinical imaging offering with Carestream in vivo portfolio purchase
This article was originally published in Clinica
Executive Summary
Bioscience and research tools specialist Bruker has agreed to buy Carestream Health's preclinical in vivo imaging portfolio from its molecular imaging business for an undisclosed fee. Bruker said the deal will add to its "broad spectrum" of preclinical imaging systems and position its in vivo products for long-term growth.